(RTTNews) -  Biopharmaceutical company, Halozyme Therapeutics, Inc. (HALO: News ) Thursday, announced additional phase II results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme with Humulin R or regular human insulin which is a mealtime insulin.

According to the company, the study also showed a significant reduction in postprandial blood glucose levels following administration of a standardized test meal and less hypoglycemia compared to Humulin R alone. These results provide additional confirmation in type 1 diabetes patients of the effects observed in an early stage study conducted in healthy volunteers.

Combinations of lispro and regular insulin plus PH20 compared to either insulin alone in type 1 diabetic patients demonstrated faster insulin absorption and a shorter blood insulin concentration
Halozyme further said, it is developing two different products to explore a maximum range of value creating opportunities: recombinant human insulin formulated with PH20 , and a rapid acting insulin analog formulated with PH20.

HALO is currently being traded at $7.04 down $0.07 or 0.98% on a volume of 0.268 million shares on the Nasdaq.

To receive FREE breaking news email alerts for Halozyme Therapeutics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com